false 0000012208 0000012208 2022-02-25 2022-02-25 0000012208 us-gaap:CommonStockMember 2022-02-25 2022-02-25 0000012208 us-gaap:CommonClassBMember 2022-02-25 2022-02-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: February 25, 2022

(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-7928

Delaware |  | 94-1381833
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

1000 Alfred Nobel Dr.

Hercules, California 94547

(Address of principal executive offices, including zip code)

(510) 724-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per share |  | BIO |  | New York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share |  | BIOb |  | New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01 | Regulation FD Disclosure.

As previously announced, Bio-Rad Laboratories, Inc. (the “Company”) plans to host an in-person investor day in New York City on Friday, February 25, 2022, at 10:30 a.m. EST. A live webcast will also be available. Registration is required to attend the event. The event will feature presentations from Norman Schwartz, Chief Executive Officer, and other key members of Bio-Rad’s executive leadership team. Members of the leadership team will also participate in a Q&A session following the presentations. A link to the event and registration will be available on the “Investor Relations” section of the Company’s website under “Conferences & Events” at www.bio-rad.com. For those who cannot participate at the scheduled time, a replay of the event, along with accompanying presentation slides will be archived on the website for up to a year following its conclusion.

On February 25, 2022, the Company issued a press release relating to the investor day and posted the Investor Day 2022 presentation on the “Investor Relations” section of its website under “Conferences & Events” at www.bio-rad.com. A copy of the Investor Day 2022 presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01 | Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. |  | Description
99.1 |  | Investor Day 2022 Presentation of Bio-Rad Laboratories, Inc. dated February 25, 2022
99.2 |  | Press Release of Bio-Rad Laboratories, Inc. dated February 25, 2022
104 |  | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  |  | BIO-RAD LABORATORIES, INC.
Date: February 25, 2022 |  |  |  | By: |  | /s/ Timothy S. Ernst
|  |  |  |  |  | Timothy S. Ernst
|  |  |  |  |  | Executive Vice President, General Counsel and Secretary